A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
← catalyst calendarNCT07023081 · readout in 268 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Prevention
Enrollment
200actual
Sites
2
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-15 | actual | When the study began enrolling |
| Primary completion | 2027-05-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pneumococcal Disease
Interventions
- Biological: 20vPnC
- Biological: 13vPnC
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants reporting prespecified local reactions within 7 days following each study intervention
measured Within 7 days of each study intervention
Percentage of participants reporting prespecified systemic events within 7 days following each study intervention
measured Within 7 days of each study intervention
Percentage of participants reporting adverse events (AEs) from the first study intervention through 1 month following the last study intervention administration
measured 1 month after the last vaccination
Percentage of participants reporting AEs from the first study intervention through 1 month following the third study intervention.
measured From the first study intervention to 1 month after the third study intervention
Percentage of participants reporting AEs from the fourth study intervention to 1 month following the fourth study intervention.
measured From the fourth study intervention to 1 month after the fourth study intervention
Percentage of participants reporting serious adverse events (SAEs) throughout the study
measured From the first study intervention to 6 months after the last study intervention
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed